2026-2030年全球寡核苷酸療法市場

全球寡核苷酸療法市場預計將從 2025 年到 2030 年成長至 186.139 億美元，預測期內複合年成長率為 19.7%。

這份關於全球寡核苷酸療法市場的報告提供了全面的分析，包括市場規模和預測、趨勢、成長要素、挑戰以及涵蓋約 25 家供應商的供應商分析。

本報告對當前市場狀況、最新趨勢和促進因素以及整體市場環境進行了最新分析。推動該市場成長的因素包括：遺傳性疾病和罕見患者疾病的上升、RNA療法監管和臨床檢驗的不斷完善，以及對精準醫療和基因組研究投資的增加。

本研究客觀地結合了一手和二手訊息，包括來自主要行業相關人員的信息。報告內容涵蓋主要公司分析、全面的市場規模數據、細分市場數據及區域分析，以及供應商格局數據。此外，報告還提供了歷史和預測的市場規模數據。

本研究指出，未來幾年，RNA編輯和新一代寡核苷酸療法的興起將是全球寡核苷酸療法市場成長的關鍵促進因素。此外，整合開發和生產夥伴關係的拓展，以及數位化技術和人工智慧驅動的藥物發現工作流程的日益普及，預計也將顯著提升市場需求。

目錄

第1章：執行摘要

第2章 Technavio 分析

• 分析定價、生命週期、顧客購買籃子、採用率和購買標準。
• 輸入的重要性及差異化因素
• 干擾因素
• 促進因素和挑戰的影響

第3章 市場狀況

• 市場生態系統
• 市場特徵
• 價值鏈分析

第4章 市場規模

• 市場的定義
• 市場區隔分析
• 2025年市場規模
• 市場展望，2025-2030年

第5章 市場規模與表現

• 2020-2024年全球寡核苷酸治療市場
• 按類型分類的細分市場分析，2020-2024 年
• 基於應用領域的細分市場分析，2020-2024 年
• 2020年至2024年最終用戶細分市場分析
• 區域區隔市場分析，2020-2024 年
• 2020-2024年各國細分市場分析

第6章 定性分析

• 人工智慧的影響：全球寡核苷酸治療市場
• 地緣政治衝突的影響：全球寡核苷酸治療市場

第7章：五力分析

第8章 市場區隔：依類型

• 比較：按類型
• 神經系統
• 癌症
• 其他
• 市場機會：按類型分類

第9章 市場區隔：依應用

• 比較：透過應用
• ASO
• RNAi
• 其他
• 市場機會：依應用領域分類

第10章 市場區隔：依最終用戶分類

• 比較：按最終用戶
• 醫院
• 專業治療中心
• 研究機構和學術機構
• 市場機會：依最終用戶分類

第11章 客戶情況

第12章 區域情勢

• 區域分類
• 區域比較
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞洲
  • 中國
  • 日本
  • 韓國
  • 印度
  • 新加坡
  • 台灣
• 世界其他地區（RoW）
  • 巴西
  • 澳洲
  • 沙烏地阿拉伯
  • 以色列
  • UAE
  • 南非
  • 阿根廷
  • 哥倫比亞
• 市場機會：按地區分類

第13章 促進因素、挑戰與機遇

• 市場促進因素
• 市場挑戰
• 促進因素和挑戰的影響
• 市場機遇

第14章 競爭格局

• 概述
• 競爭格局
• 中斷狀況
• 產業風險

第15章 競爭分析

• 公司簡介
• 公司排名指標
• 企業市場定位
• Agilent Technologies Inc.
• Alnylam Pharmaceuticals Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bachem AG
• Biogen Inc.
• Catalent Inc.
• Ionis Pharmaceuticals Inc.
• Jazz Pharmaceuticals Plc
• Lonza Group Ltd.
• Novartis AG
• Novo Nordisk AS
• Sanofi SA
• Sarepta Therapeutics Inc.
• Thermo Fisher Scientific Inc.

第16章附錄

The global oligonucleotide therapeutics market is forecasted to grow by USD 18613.9 mn during 2025-2030, accelerating at a CAGR of 19.7% during the forecast period. The report on the global oligonucleotide therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of genetic and rare diseases, expanding regulatory and clinical validation of rna therapeutics, growing investment in precision medicine and genomic research.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global oligonucleotide therapeutics market is segmented as below:

By Type

• Neurological
• Cancer
• Others

By Application

• ASOs
• RNAi
• Others

By End-User

• Hospitals
• Specialty treatment centers
• Research institutes and academic centers

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the shift toward rna editing and next-generation oligonucleotide modalities as one of the prime reasons driving the global oligonucleotide therapeutics market growth during the next few years. Also, expansion of integrated development and manufacturing partnerships and increasing adoption of digital and ai enabled discovery workflows will lead to sizable demand in the market.

The report on the global oligonucleotide therapeutics market covers the following areas:

• Global oligonucleotide therapeutics market sizing
• Global oligonucleotide therapeutics market forecast
• Global oligonucleotide therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global oligonucleotide therapeutics market vendors that include Agilent Technologies Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Bachem AG, Biogen Inc., Catalent Inc., Corden Pharma Intl. GmbH, Ionis Pharmaceuticals Inc., Jazz Pharmaceuticals Plc, Lonza Group Ltd., Nitto Denko Avecia Inc., Novartis AG, Novo Nordisk AS, NS Pharma Inc., Sanofi SA, Sarepta Therapeutics Inc., Syngene International Ltd., Thermo Fisher Scientific Inc., WuXi AppTec Co. Ltd.. Also, the global oligonucleotide therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Oligonucleotide Therapeutics Market 2020 - 2024
  • Historic Market Size - Data Table on Global Oligonucleotide Therapeutics Market 2020 - 2024 ($ million)
• 5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.3 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.4 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global oligonucleotide therapeutics market
• 6.2 Impact of geopolitical conflicts on global oligonucleotide therapeutics market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Neurological - Market size and forecast 2025-2030
• 8.4 Cancer - Market size and forecast 2025-2030
• 8.5 Others - Market size and forecast 2025-2030
• 8.6 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by Application

• 9.1 Market segments
• 9.2 Comparison by Application
• 9.3 ASOs - Market size and forecast 2025-2030
• 9.4 RNAi - Market size and forecast 2025-2030
• 9.5 Others - Market size and forecast 2025-2030
• 9.6 Market opportunity by Application
  • Market opportunity by Application ($ million)

10 Market Segmentation by End-user

• 10.1 Market segments
• 10.2 Comparison by End-user
• 10.3 Hospitals - Market size and forecast 2025-2030
• 10.4 Specialty treatment centers - Market size and forecast 2025-2030
• 10.5 Research institutes and academic centers - Market size and forecast 2025-2030
• 10.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 South Korea - Market size and forecast 2025-2030
  • 12.5.4 India - Market size and forecast 2025-2030
  • 12.5.5 Singapore - Market size and forecast 2025-2030
  • 12.5.6 Taiwan - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Australia - Market size and forecast 2025-2030
  • 12.6.3 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.4 Israel - Market size and forecast 2025-2030
  • 12.6.5 UAE - Market size and forecast 2025-2030
  • 12.6.6 South Africa - Market size and forecast 2025-2030
  • 12.6.7 Argentina - Market size and forecast 2025-2030
  • 12.6.8 Colombia - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Rising prevalence of genetic and rare diseases
  • Expanding regulatory and clinical validation of RNA therapeutics
  • Growing investment in precision medicine and genomic research
• 13.2 Market challenges
  • High development complexity and clinical attrition
  • Stringent regulatory requirements
  • Limited delivery efficiency across diverse tissue targets
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Shift toward RNA editing and next-generation oligonucleotide modalities
  • Expansion of integrated development and manufacturing partnerships
  • Increasing adoption of digital and AI enabled discovery workflows

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Agilent Technologies Inc.
  • Agilent Technologies Inc. - Overview
  • Agilent Technologies Inc. - Business segments
  • Agilent Technologies Inc. - Key news
  • Agilent Technologies Inc. - Key offerings
  • Agilent Technologies Inc. - Segment focus
  • SWOT
• 15.5 Alnylam Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc. - Overview
  • Alnylam Pharmaceuticals Inc. - Product / Service
  • Alnylam Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.6 Astellas Pharma Inc.
  • Astellas Pharma Inc. - Overview
  • Astellas Pharma Inc. - Product / Service
  • Astellas Pharma Inc. - Key news
  • Astellas Pharma Inc. - Key offerings
  • SWOT
• 15.7 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Business segments
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Segment focus
  • SWOT
• 15.8 Bachem AG
  • Bachem AG - Overview
  • Bachem AG - Business segments
  • Bachem AG - Key news
  • Bachem AG - Key offerings
  • Bachem AG - Segment focus
  • SWOT
• 15.9 Biogen Inc.
  • Biogen Inc. - Overview
  • Biogen Inc. - Product / Service
  • Biogen Inc. - Key news
  • Biogen Inc. - Key offerings
  • SWOT
• 15.10 Catalent Inc.
  • Catalent Inc. - Overview
  • Catalent Inc. - Product / Service
  • Catalent Inc. - Key offerings
  • SWOT
• 15.11 Ionis Pharmaceuticals Inc.
  • Ionis Pharmaceuticals Inc. - Overview
  • Ionis Pharmaceuticals Inc. - Product / Service
  • Ionis Pharmaceuticals Inc. - Key news
  • Ionis Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.12 Jazz Pharmaceuticals Plc
  • Jazz Pharmaceuticals Plc - Overview
  • Jazz Pharmaceuticals Plc - Product / Service
  • Jazz Pharmaceuticals Plc - Key news
  • Jazz Pharmaceuticals Plc - Key offerings
  • SWOT
• 15.13 Lonza Group Ltd.
  • Lonza Group Ltd. - Overview
  • Lonza Group Ltd. - Business segments
  • Lonza Group Ltd. - Key news
  • Lonza Group Ltd. - Key offerings
  • Lonza Group Ltd. - Segment focus
  • SWOT
• 15.14 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.15 Novo Nordisk AS
  • Novo Nordisk AS - Overview
  • Novo Nordisk AS - Business segments
  • Novo Nordisk AS - Key offerings
  • Novo Nordisk AS - Segment focus
  • SWOT
• 15.16 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 15.17 Sarepta Therapeutics Inc.
  • Sarepta Therapeutics Inc. - Overview
  • Sarepta Therapeutics Inc. - Product / Service
  • Sarepta Therapeutics Inc. - Key offerings
  • SWOT
• 15.18 Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc. - Overview
  • Thermo Fisher Scientific Inc. - Business segments
  • Thermo Fisher Scientific Inc. - Key news
  • Thermo Fisher Scientific Inc. - Key offerings
  • Thermo Fisher Scientific Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations